Vascular Interventional Devices: New Avenues For Growth
Manufacturers are finding it harder to innovate in the vascular interventional devices as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in renal denervation, drug-coated balloons, and renal artery stenting; still there are some promising areas, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.
You may also be interested in...
US Cardiovascular Sector In Need Of A Jolt From First-of-A-Kind Balloons And Stents
The US interventional cardiology market will continue to exhibit weak growth in the next five years, but there will be pockets of healthy growth, such as in coronary thrombectomy devices. According to Medtech Insight’s latest report on the sector, growth to 2018 will also be supported by several other factors.
In Atrial Fibrillation, SentreHEART Lassos An Advantage
SentreHEART is operating in one of the most promising device spaces in stroke: percutaneous left atrial appendage closure. Unlike early movers, SentreHEART doesn’t leave an implant behind in the heart, and its LARIAT procedure might have unique benefits in addressing not only the stroke risk that comes with atrial fibrillation, but also AF itself.
Emerging Markets Earnings Roundup: Abbott (Part 2)
Abbott Laboratories said it has turned a corner after dairy product recalls last year and that China is squarely in focus, but known unknowns remain.